Is LCTX or LENZ more undervalued in 2026?

CirclFi compares Lineage Cell Therapeutics, Inc. (LCTX) and LENZ Therapeutics, Inc. (LENZ) using 13 institutional-grade valuation models. LCTX has a Quality of Company score of 6.7/10 while LENZ scores 5.3/10.

Which is a better buy — LCTX or LENZ?

Compare intrinsic values from 13 independent models against current market prices. CirclFi also calculates Value Trap scores. This is not financial advice — conduct your own analysis.

How do LCTX and LENZ valuations compare?

LCTX at $1.33 and LENZ at $7.78 are compared across Bayesian DCF, EPV, EROIC Spread, First Chicago, Markov DDM, and 8 additional models.

LCTX vs LENZ Valuation Comparison 2026 — Intrinsic Value Analysis

LCTX

Biological Products, (No Diagnostic Substances)

Lineage Cell Therapeutics, Inc.

Quality

6.7

out of 10

Value Trap

SAFE

Price

$1.33

Last close

Models

9/13

Active

LENZ

Biological Products, (No Diagnostic Substances)

LENZ Therapeutics, Inc.

Quality

5.3

out of 10

Value Trap

SAFE

Price

$7.78

Last close

Models

11/13

Active

Model-by-Model Comparison

Model	Type	LCTX Fair Value	LCTX Upside	LENZ Fair Value	LENZ Upside
Bayesian DCF	Intrinsic	$0.33	-75.1%	$2.33	-70.1%
Earnings Power Value	Intrinsic	—	—	$2.46	-72.2%
EROIC Spread	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
First Chicago	Scenario	$•••.••	••.•%	$•••.••	••.•%
ML-RIV	Intrinsic	$0.23	-82.9%	$1.42	-81.2%
Dynamic NAV	Asset-Based	$•••.••	••.•%	$•••.••	••.•%
PWERM	Option-Based	$•••.••	••.•%	$•••.••	••.•%
Regime Cross-Sectional	Relative	$•••.••	••.•%	$•••.••	••.•%
Sentiment SOTP	Hybrid	$•••.••	••.•%	$•••.••	••.•%
CUCE Ensemble	Ensemble	$•••.••	••.•%	$•••.••	••.•%
FTNN Topology	Relative	$•••.••	••.•%	$•••.••	••.•%

🔒

Unlock Full 13-Model Comparison

Access all valuation models for LCTX vs LENZ — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.

Access Full Analysis — From $27/mo →

LCTX vs LENZ — Which Stock Is More Undervalued?

LCTX scores higher with a 6.7/10 quality rating vs LENZ's 5.3/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.

Comparing Lineage Cell Therapeutics, Inc. (LCTX) and LENZ Therapeutics, Inc. (LENZ) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.

LCTX currently trades at $1.33 with a QOC of 6.7/10, while LENZ trades at $7.78 with a QOC of 5.3/10.

Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).